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Abstract 
Introduction The emergence of drug resistance mutations (DRMs) has been a major threat for 
successful lifelong combination antiretroviral therapy (cART), especially for HIV-vertically infected 
children within the context of the prevention of mother-to-child transmission (PMTCT). This study 
aimed to evaluate DRMs amongst immune competent treatment-naïve children in Cameroon.   
Methods A cross-sectional study was conducted between 2015 and 2016 amongst 55 proxy consented 
HIV-1 positive children, aged 9 months to 6 years. They were all immune competent, cART naïve and 
with unknown history of PMTCT. CD4 cell counts and genotypic drug resistance testing were 
performed using standard methods. 
Results Levels of DRMs to protease (PR) inhibitors (PIs), nucleoside reverse transcriptase inhibitors 
(NRTIs) and non-NRTIs were 27.6%, 3.7% and 40.7%, respectively. Only minor DRMs were observed 
for PR. The observed mutations for NRTI were K65R, T215I and K219E (33.0% each) and for NNRTI: 
V106M, Y181C and Y188H (6.0% each). Only minor accessory mutations were found in the integrase 
(IN) region. 
Conclusion Despite widely available cART we still observe naïve HIV children, especially from the 
rural communities. We observe that a proportion of study participants had HIV-1 drug resistance 
associated mutations (RAMs). Data generated could help strengthen the current PMTCT programmes 
within the country. There is a need to upscale approaches for drug resistance testing for children in 
Cameroon and many other resource-limited settings. 
 
Keywords HIV, resistance, prevention of mother-to-child-transmission (PMTCT), infants, 
Cameroon, treatment-naïve, immune competent 
 
Introduction 
HIV-1 is still a major public health problem 
with approximately 36.7 million people living 
with HIV/AIDS globally.1 Sub-Saharan Africa1                                                         
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remains the worst affected as the number of HIV 
patients continues to rise.2 In Cameroon, HIV 
remains a huge health burden with approximately                                                                                    
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600,000 to 720,000 infected adults and 53,000 to 
63,000 infected children of 0-14 years.3,4 The 
introduction of combination antiretroviral 
therapy (cART) has seen a considerable reduction 
of the pandemic globally. In 2016, 19.5 million 
people were able to access cART (UNAIDS, 
2017) – approximately a 19% increase from 15.8 
million in June 2015, attaining the global 
treatment goal of 15 million people on cART by 
2015.3 More coverage is ongoing, especially with 
the rolling-out of programmes like prevention of 
mother-to-child transmission (PMTCT) and the 
90-90-90 concept by the United Nations (UN) 
program on HIV/AIDS that started in 2013 
focusing on the “Sustainable Development 
Goals” of ending the AIDS pandemic by 2030.3 
Despite these commendable efforts by the global 
community, the emergence of resistance to cART 
is a serious threat for the overall success of HIV 
treatment and this requires continued 
surveillance. In Cameroon, the HIV-1 drug 
resistance rates stand at approximately 3.6% for 
children as reported by the Cameroon national 
AIDS committee (2016).5 The implementation of 
cART, especially in pregnant women and young 
infected children, has shown a notable reduction 
in the disease.5 Unfortunately, epidemiological 
data generated on the pediatric HIV population 
on cART in Cameroon are limited. Cameroon 
follows the WHO recommendation for cART, 
with the first-line treatment regimen of two 
nucleoside reverse transcriptase inhibitors 
(NRTI), mainly tenofovir (TDF) or zidovudine 
(AZT) and lamivudine (3TC), and one non-
nucleoside reverse transcriptase inhibitor 
(NNRTI), either efavirenz (EFV) or nevirapine 
(NVP). At the time of cART initiation the 
following recommendations were given for 
children under the age of 3 and under 10 kg: 
either AZT, stavudine (d4T) or abacavir (ABC), 
with either EFV or NVP as NNRTI. From 2006, 
the threshold of CD4 cell percentage levels for 
severe immunodeficiency was less than 25% for 
infants 11 months or less, less than 20% for 
children aged 12 to 35 months, and less than 
15% for children 3 years or older. Pre-treatment 
viral load was not mandated prior to cART 
initiation. 
There has been substantial progress in the 
implementation of the simplified WHO 
approach, since the cART services have been 
decentralized.6 According to reports gathered 
from stakeholders like The Joint United Nations 
Programme on HIV/AIDS (UNAIDS), the 
United States Centers for Disease Control and 
Prevention (CDC), together with the Cameroon 
government, there are about 585 PMTCT clinics 
across various regions in Cameroon.3 Despite the 
huge success and availability of cART, it leads to 
an increased prevalence of HIV drug-resistant 
strains. It is often difficult to study the prevalence 
of HIV resistance associated mutations (RAMs) 
in resource limited settings, such as the 
conditions found in Cameroon. This is further 
fueled by insufficient patient adherence to 
treatment or incomplete suppression of viral 
replication during treatment, potentially 
associating the emergence of drug-resistant 
viruses.6 There are limited centers in Cameroon 
performing HIV-1 resistance testing and these are 
found at the major research laboratories in the 
main cities of Yaoundé and Douala. Diagnostic 
resistance testing remains too expensive to 
implement despite government efforts to 
subsidize. The aim of this study was to investigate 
the HIV resistance patterns from an infant 
population from rural and urban surroundings of 
Yaoundé, Cameroon. 
 
Methods 
Ethics statement 
Ethical clearances were obtained from the 
Cameroon National Ethical Committee and the 
Health Research Ethics Committee at 
Stellenbosch University with reference numbers 
049/CNE/SE/2015 and N14/10/130, 
respectively. A formal study agreement has been 
signed by the two centers to conduct joint 
research. 
Study design and procedures 
In a cross-sectional study conducted between 
2015-2016, 55 HIV-1 positive naïve and treated 
children were recruited from The Chantal Biya 
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Foundation Hospital and other health 
institutions around Yaoundé (Figure 1). Two 
main reasons hampered the enrollment process 
for this particular study. First, the majority of the 
babies were under critical clinical observation 
and most caregivers refused to participate in the 
study. Second, most infants admitted to the 
different hospitals had a recorded history of 
severe anemia and were excluded. For the 
patients who were included, a proxy consent 
form was obtained from the caregivers, which 
was generated using a standard designed 
questionnaire and included all the necessary 
demographic data. The majority of the caregivers 
lived in rural settings where health facilities are 
limited. We collected 3 mL of venous whole 
blood under standard conditions in EDTA 
anticoagulated tubes. 
 
 
Analysis sites 
Samples were analyzed at the 
Immunovirology laboratory of the Center for the 
Study and Control of Communicable Diseases 
(CSCCD), University of Yaoundé I, Cameroon, 
and the Division of Medical Virology, 
Stellenbosch University, South Africa. 
 
HIV screening 
HIV serology status was confirmed based on 
the Cameroon national algorithms, which 
involves the use of two HIV rapid diagnostic 
tests and a confirmation with a p24 
antigen/antibody detection ELISA kit. The 
Alere Determine™ HIV-1/2 (Abbott 
Laboratories, Abbott Park, Illinois, USA) and 
the SD Bioline HIV 1/2 version 3.0 (Standard 
Diagnostics, Inc., Kyonggi-do, Korea) were used 
with an ELISA antigen antibody kit (Integral 
Enzygnost ELISA kits, Siemens, Paris, France). 
All tests were performed following the 
manufacturer’s guidelines. 
 
 
HIV viral load determination 
The RT-PCR Amplicor 1.5 commercial viral 
load kit was used to determine the patients’ 
plasma HIV viral load (Roche Diagnostic 
 
Figure 1. A map of the different health districts around Yaoundé, Cameroon. 
The samples were obtained from the 5 different health districts surrounding the CSCCD and the 
University of Yaoundé I, Cameroon. The map was created with scribble maps (www.scribblemaps.com). 
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Systems, Pleasanton, California, USA). The 
assay was performed with a prepared master mix 
containing oligonucleotide primers specific to 
regions of the HIV-1 gag genes with upstream 
sense primers of Sk145 (5’-
ACTGGGGGGACATCAACCACCCATGCA
AT-3′) and the downstream antisense of 
SKCC1B (5’-
TACTAGTAGTTCCTGCTATGTCACTTCC-
3′) (HXB2 position 1359-1513). The minimum 
detection limit of the kits was 1.67 log10 or less 
than 40 copies/mL. 
 
Determination of CD4+ cell counts and 
percentages 
Fifty µL of whole blood collected in EDTA 
tubes were used for CD4 absolute and 
percentage counts. This was based on the 
principle of immunophenotyping using an 
automated Fluorescence Activated Cell Sorting 
(FACS) Count Analyzer with the BD 
FACSCount tri CD4/CD8/CD3 reagent kit 
(BD Biosciences, San Jose, California, USA). 
Samples, including quality controls, were 
analyzed based on the manufacturers’ guidelines. 
 
HIV resistance testing 
HIV-1 resistance testing was done as 
previously described.7,8 Briefly, viral RNA was 
extracted using the Qiagen Viral RNA extraction 
kit using the manufacturer’s instructions 
(Qiagen, Hilden, Germany). A one-step RT-PCR 
reaction was performed with the SuperScript® 
III One-Step RT-PCR System with 
Platinum®Taq DNA Polymerase kit (Invitrogen, 
USA), followed by a second round PCR with 
GoTaq DNA polymerase (Promega, Wisconsin, 
USA). We amplified a 507 bp region of the HIV-
1 protease (PR) (HXB2 position 2136-2650) and 
a 798 bp region of the reverse transcriptase (RT) 
(HXB2 position 2530-3334). We also amplified a 
small 250 bp fragment of the HIV integrase (IN) 
with the Unipol primers (HXB2 position 4025-
4275). The primers were previously designed to 
ensure the PCR amplification and detection of 
the majority of HIV variants found in 
Cameroon.9 All PCR products were sequenced 
using the BigDye™ Terminator Cycle 
Sequencing Ready Reaction Kit and analyzed on 
an ABI Prism 3130 automated DNA sequencer 
(Applied Biosystems, Foster City, California, 
USA). Overlapping DNA fragments were 
assembled using Sequencer version 5.1 (Gene 
Codes Corporation, Ann Arbor, Michigan, 
USA) using the default parameter settings, with 
sequence quality above 75.0%. The sequences 
were characterized for RAMs according to the 
Stanford University HIV Genotypic Resistance 
Interpretation Algorithm version 8.3 
(https://hivdb.stanford.edu/). 
 
Statistical analyses 
Data for the study were collected in an Excel 
sheet and analyzed using the Graph Pad Prism 
5.0 software programme. The CD4 percentages 
were evaluated using Fisher’s exact test. For the 
baseline characteristics and variables of gender 
and sex we applied the Chi-squared test.  
 
Results  
Demographic information 
Of the 55 children recruited, 32 (58.0%) 
were females and 23 (42.0%) were males. Their 
ages ranged from 9 months to 6 years, with the 
mean age of 2.5 years old. Most mothers (34; 
62.0%) were naïve to cART, while 21 (38.0%) 
were exposed to cART during their pregnancy. 
The demographic data are summarized in Table 
1. 
 
Table 1. Clinical and demographic information 
 
Number of 
patients 
(n=55) 
Female: 32 (58%) 
Male: 23 (42%) 
Age 
Youngest: 9 months 
Eldest: 6 years 
Mean: 2.5 years 
Settings 
Rural: 41 (74%) 
Urban: 14 (26%) 
Treatment 
cART naïve mothers: 34 (62%) 
cART exposed pregnant mothers: 21 
(38%) 
CD4 cell 
count 
Lowest: 15% (500 cells/cmm) 
Highest: 44% (2000 cells/cmm) 
Mean: 958 cells/cmm 
Viral load 
Lowest: 4.6 log10 
Highest: 5.87 log10 
Mean: 4.40 log10 
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CD4 cell count and viral load 
CD4 percentages and absolute counts ranged 
between 30% and 44.0% (median 33.0%, 500-
2000 cells/cmm with a mean of 957), 
respectively. All patients were considered 
immunocompetent based on the CDC immune 
category classification system. The HIV-1 plasma 
RNA viral loads ranged between 4.6 and 5.87 
log10 or (23,000 to 150,000) copies per milliliter 
with a median of 4.96. 
 
PCR amplification and sequencing 
We amplified and successfully sequenced 
37/55 (67.3%) of our cohort samples for at least 
one of the HIV fragments analyzed. For the PR 
we could sequence 29 (52.7%) fragments, for the 
RT 27 (49.1%) and for the integrase (IN) 28 
(50.9%). This was most likely due to the high 
HIV genetic variability found in the region, as all 
the major HIV groups and subtypes are found in 
the region. 
 
HIV-1 resistance associated mutations 
The observed numbers of RAMs against PI, 
NRTI and NNRTI are listed in Table 2.  
 
 
Table 2. Observed RAMs found in the study 
 
 
Number 
of 
samples 
analyzed 
Number 
of samples 
with 
RAMS 
Percentage 
Major 
NRTI 
27 1 3.7% 
Major 
NNRTI 
27 11 40.7% 
Minor PI 29 8 27.6% 
NRTI – nucleoside reverse transcriptase inhibitors; 
NNRTI – non-nucleoside reverse transcriptase 
inhibitors; PI – protease inhibitors; RAM – 
resistance associated mutations. 
 
 
We noticed no major PR RAMs in the 29 
sequences examined. We detected minor PI 
RAMs in 8 sequences. L10I, observed in 4/29 
sequences (20.7%), is a polymorphic accessory 
mutation, while K20I, observed in 20/29 
sequences (62.1%) is the consensus amino acid 
in subtype G and CRF02_AG. Other minor 
mutations observed include: L10V (n=2; 6.9%), 
K20M (n=1; 3.5%) and G48R (n=1; 3.5%). For 
the 27 RT sequences evaluated we observed 
NNRTI resistance associated mutations in 11 of 
the 27 sequences (40.7%). These include the 
mutations V106M, Y181C and Y188H. The 
V106M mutation indicates high-level resistance 
to NVP and EFV, Y181C indicates reduced 
susceptibility to NVP, ETR, RPV and EFV, 
while Y188H indicates reduced susceptibility to 
NVP and EFV. One patient had multiple major 
NNRT and NRTI RAMs (Table 3). The NRTI 
mutations observed for this patient were K65R, 
T215I and K219E. The K65R mutation 
indicates high-level resistance to TDF, DDI and 
D4T, but low to intermediate-level resistance to 
3TC and FTC. The T215I mutation indicates 
intermediate to high-level resistance to AZT and 
D4T, with low-level resistance to ABC, DDI and 
TDF. The K219E mutation, with accessory 
thymidine analogues mutations (TAMs), is 
associated with reduced susceptibility to AZT 
and possibly to D4T. These mutations indicate 
that this strain is highly resistant to all current 
classes of NRTI and NNRTI drugs. 
 
Discussion 
In this study we assessed the HIV resistance 
patterns from a cohort of 55 treatment naïve 
infected infants from Yaoundé, Cameroon. The 
majority of the study participants resided in rural 
areas, where much less attention is given to 
HIV/AIDS infections and healthcare. Most of 
the children had CD4% and absolute values 
within the therapeutic normal range, namely 
>30% and >500 copies/mL.3 The value confers 
their immune-competent status as outlined in the 
WHO and CDC treatment guideline for HIV 
immunological staging.  
 
In this study, levels of DRMs to PIs, NRTIs 
and NNRTIs were 27.6%, 3.7% and 40.7%, 
respectively. This includes one infant who had 
RAMs against multiple drugs. In a previous study 
in Cameroon Fokam et al. (2011) showed low 
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levels of HIV drug resistance in therapy naïve 
pediatric patients (4.9%), but high levels in 
patients failing first-line cART (90%).10 Similarly, 
Ceccarelli et al. (2012) showed a RAM prevalence 
rate of 8.2% in therapy naïve children from 
Yaoundé, Cameroon.11 In other previous studies 
done in Cameroon on therapy naïve adult 
patients a prevalence between 4% and 8% was 
observed for both NRTI and NNRTIs.12,13,14 
These studies suggest that resistance testing 
should become part of routine HIV diagnostics. 
There is a need to standardize resistance testing 
protocols, especially where there is a high 
endemic genetic diversity of HIV. Access to 
genotyping and resistance testing has been 
hampered by high cost and absence of 
technology, especially in the rural regions. The 
assays and data gained can help manage HIV 
patients failing cART by providing baseline 
knowledge on the RAMs.15 We recommend that 
an HIV resistance test be given before initiating 
cART and that patients, especially infants have 
routine clinical testing to ensure the maximum 
efficiency of cART. Implementing resistance 
testing will also help avoid extra costs that may 
incur. Second-line therapy is already considered 
more expensive, and ineffective treatment can 
lead to additional morbidity with opportunistic 
infections, which may also become expensive to 
treat.16,17 
Another major concern is the high number of 
infants still being born HIV positive from 
exposed mothers, even though widespread 
PMTCT programmes have been implemented in 
the country, as recommended by the WHO 
(2015).1 To minimize HIV transmission, PMTCT 
programmes need to be improved. Access to 
clinics and healthcare facilities remain difficult 
and many HIV positive patients are too easily lost 
to follow-up.5,18 Thus, infrastructure and access to 
facilities in rural Cameroon need to be improved. 
As yet, there are no core facilities to perform 
basic viral load testing, which is only done at 
major centers. The current estimates show that 
over a million children will still require cART by 
2020.19 The WHO programmes should be 
robustly implemented, as they look to support 
regimens that are more simplified, less toxic, have 
higher genetic barriers and would ultimately 
require less clinical monitoring for each patient, 
while maintaining therapeutic efficacy.19 
The study limitations include the relatively 
small size of the study cohort, which was 
especially due to the diagnosis and treatment 
approach. The lack of follow-up and treatment 
and adherence data from the mothers is also a 
notable concern. 
  
 
Conclusions   
The observed drug RAMs in treatment naïve 
infants in our study raise concerns on the 
availability and effectiveness of the current 
treatment programmes. There is a need to have 
improved, cost effective HIV diagnostic and 
resistance assays for the region. The data 
generated from this study would help to 
strengthen HIV monitoring and resistance 
Table 3. Observed resistance associated mutations for one patient in the study (multiple resistance 
associated mutations against NRTIs and NNRTIs). 
 
NRTI Comments 
K65R High-level resistance to TDF, ddI, ABC and d4T. Low to intermediate-level resistance to 3TC and FTC. 
T215I Intermediate to high-level resistance to AZT and d4T. Low-level resistance to ABC, ddI and TDF. 
K219E K219Q/E are accessory TAMs associated with reduced susceptibility to AZT and possibly d4T. 
NNRTI  
V106M High-level resistance to NVP and EFV. 
Y181C Reduces susceptibility to NVP, ETR, RPV, and EFV. 
Y188H Causes reduced susceptibility to NVP and EFV. 
ABC – abacavir; AZT – zidovudine; d4t – stavudine; ddI – didanosine; EFV – efavirenz; FTC – emtricitabine; NRTI – 
nucleoside reverse transcriptase inhibitors; NNRTI – non-nucleoside reverse transcriptase inhibitors; NVP – 
nevirapine; PI – protease inhibitors; RAM – resistance associated mutation; RPV – rilpivirine; TAMs – thymidine 
analog mutations; TDF – tenofovir disoproxil fumarate; 3TC – lamivudine.   
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testing in Cameroon and many other sub-
Saharan African Countries. 
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